Matinas BioPharma (MTNB)
Developer of lipid nanocrystal delivery technology for oral antifungal treatment.
Something off on this page? Send us feedback.
Develops oral drug-delivery technology around MAT2203, an investigational oral amphotericin B formulation for invasive fungal infections. With no approved products or sales infrastructure, its near-term economics depend on planned asset-sale and business-combination transactions.
Develops lipid nanocrystal delivery technology intended to carry medicines orally to target cells. Its only named clinical program, MAT2203, is an oral formulation of amphotericin B for invasive fungal infections, designed to reduce the toxicity and administration burdens associated with intravenous amphotericin products.
Operates without approved products, product sales, internal manufacturing, or commercial sales infrastructure. A minimal staff is centered on asset preservation and transaction execution while the planned late-stage MAT2203 trial remains paused; further development requires a partner or additional funding, third-party manufacturing, and technology transfer.
Is pursuing linked, unclosed agreements to sell MAT2203 and the LNC platform to Azurity Pharmaceuticals and combine the remaining public company with GH Power. Transaction closing depends on approvals, financing, court and securities-registration steps, and NYSE American listing approval.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $761.0K · Total debt $6.0K · Total assets $3.4M · Shareholders' equity $1.8M
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$1.3M
No dividends on record.
| Institutions28 holders · as of Mar 31, 2026 | 2.41% | 354.4K shares | |
| Insiders1 holder · as of Aug 13, 2026 | 7.90% | 1.16M shares | |
| Strategic holders1 holder · as of Jul 14, 2026 | 8.89% | 1.31M shares | |
| Otherremainder | 80.80% | 11.87M shares |
14.69M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (14.69M in the company's Sep 3, 2026 report, 6.41M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Hezbay Holdings LLCStrategic | 8.89% | 1.31M | 13Gfiled Jul 14, 2026 ↗ |
Adam K. SternInsider10 percent owner | 7.90% | 1.16M | Form 4filed Aug 13, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.44% | 65,170 | 13Fas of Mar 31, 2026 |
Citadel Advisors LLCInstitution | 0.35% | 51,698 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 0.34% | 49,650 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
